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In the B cell compartment, tolerance to many 
self proteins is actively maintained by either 
purging self-reactive B cells from the repertoire 
through clonal deletion and receptor editing or 
by functionally silencing them through the in-
duction of anergy (1–5). However, these pro-
cesses are clearly incomplete, as B cell–driven 
autoimmune responses still occur. A prime ex-
ample is the K/BxN mouse model of rheuma-
toid arthritis in which mice spontaneously 
develop a T and B cell–dependent infl  am-
matory joint disease by 4–5 wk of age (6). 
  Autoantibodies are key mediators in arthritis 
induction and by themselves can transfer dis-
ease to most naive strains of mice (7). In this 
model, the autoantigen for both the KRN 
transgenic (tg) T cells and non-tg B cells has 
been identifi  ed as the glycolytic enzyme glu-
cose-6-phosphate-isomerase (GPI) (8). It re-
mains unclear how autoreactive B and T cells 
escape tolerance induction to this ubiquitously 
expressed autoantigen and initiate the patho-
genic autoantibody response.
It is diffi   cult to study the mechanisms of 
tolerance induction for autoreactive B cells in 
unmanipulated animals because of their low 
precursor frequency. The use of Ig tg models 
has been invaluable to increase the frequency of 
autoreactive B cells, allowing their fate to be 
tracked in both healthy and autoimmune mice. 
Initial studies used high affi   nity somatically mu-
tated Ig transgenes directed toward model or 
disease-associated antigens (Ags) and defi  ned 
several fates for autoreactive B cells in nonauto-
immune mice, including clonal deletion, an-
ergy, and receptor editing (1–5, 9–13). These 
models were extremely useful and identifi  ed the 
mechanisms used to induce tolerance in B cells 
with high affi   nity Igs. However, most B cells 
undergoing tolerance induction in the BM are 
not somatically mutated, and those that are 
able to escape tolerance induction most likely 
express Igs with low affi   nity for autoantigens 
(14–16). Studies using 10–1,000-fold lower af-
fi  nity Ig B cell receptor transgenes demonstrate 
either only partial tolerance or antigenic igno-
rance in the autoreactive B cell compartment 
(17–19). Collectively, these studies demonstrate 
that B cells with low affi   nity Igs may be able to 
escape tolerance mechanisms normally induced 
in B cells with high affi   nity Igs. It is from these 
low affi   nity B cell populations that the autoim-
mune response is likely to initiate.
Mature peripheral B cells can bedivided into 
two main subsets based on surface phenotype: 
recirculating follicular B cells (B220+CD1dlow-
CD21/35intCD23int) and marginal zone (MZ) 
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B cells (B220+CD1dhighCD21/35highCD23low) (20). These 
populations are also physically segregated into diff  erent com-
partments. Follicular B cells are found in both the spleen and 
LN, whereas MZ B cells are localized exclusively to the 
spleen where they are separated from the B cell follicle by the 
marginal sinus (21). MZ B cells are a rare nonrecirculating 
B cell population that has been shown to be easily activated 
by low levels of antigen (Ag), to be potent APCs for naive 
T cells, and has been implicated in autoreactive B cell re-
sponses (22, 23). Engagement by self-Ag drives the selection 
of B cells into the MZ compartment; however, it remains 
controversial whether this is dependent on high or low affi   n-
ity interactions (21, 22, 24, 25).
To understand how GPI-reactive B cells escape tolerance 
induction to the ubiquitously expressed autoantigen GPI, 
it was important at the outset to establish how their tolerance 
was induced/maintained in nonarthritic mice. To increase 
the frequency of GPI-reactive B cells and follow their fate in 
nonautoimmune mice, we generated low affi   nity anti-GPI 
Ig tg mice, termed VH147 tg mice. VH147 tg mice are H 
chain alone tg mice in which GPI-reactive B cells are identi-
fi  able by their ability to bind GPI in a fl  ow cytometry–based 
assay, allowing for the simultaneous detection of multiple 
VH147 H chain/endogenous L chain pairs. Therefore, these 
mice off  er the unique opportunity to follow the fate of an 
oligoclonal repertoire of low affi   nity GPI-reactive B cells in 
the context of a diverse nonautoimmune B cell repertoire.
In this study, we demonstrate that low affi   nity GPI-binding 
B cells populated both the spleen and the LN of nonautoim-
mune mice but were dramatically enriched in the MZ of the 
spleen. Surprisingly, although the anti-GPI B cells showed 
evidence of autoantigen encounter beginning in the BM, 
no imprint of tolerance was evident and the GPI-reactive 
B cells remained functionally competent to proliferate and 
secrete Ig. Importantly, only the anti-GPI B cells found in 
the expanded MZ population up-regulated activation mark-
ers and spontaneously diff   erentiated into autoantibody-
  secreting cells in vivo. Although the follicular/LN anti-GPI 
B cells were ignorant to self-Ag in nonautoimmune mice, 
they were recruited into the autoimmune response by GPI-
specifi  c T cell help in vivo. Collectively, these data demon-
strate that low affi   nity self-reactive B cells can participate in 
autoantibody responses in both T cell–dependent and –indepen-
dent mechanisms.
RESULTS
Generation and characterization of KRN5-147 
hybridoma and VH147 tg mice
We wished to examine how B cell tolerance to GPI was in-
duced in nonautoimmune mice in a physiologically relevant 
context. Ig tg mice using only a H chain transgene have been 
used in past studies to increase the frequency of Ag-specifi  c 
B cells while retaining a diverse B cell repertoire (12, 13, 22). 
In this study, we generated H chain alone tg mice with the aim 
of allowing the tg H chain to pair with endogenous L chains 
in the mouse to form both GPI- and non-GPI–binding 
B cells, thus maintaining a polyclonal B cell repertoire. 
To create a low affi     nity anti-GPI Ig tg mouse, candidate 
GPI-binding Igs were identifi  ed in hybridoma panels gener-
ated from K/BxN mice at the initiation of arthritis. The goal 
was to isolate spontaneously arising anti-GPI Igs that were 
present in the early phase of arthritis, thus hypothesizing that 
these would be from B cells responsible for the induction of 
the autoimmune response.
One hybridoma, KRN5-147 (anti-GPI IgG1), was se-
lected based on its ability to bind an epitope on GPI that was 
prevalent in arthritic K/BxN serum (unpublished data). In ad-
dition, it had a relatively low affi   nity for GPI (KD 2 × 10−6) 
by surface plasmon resonance and had an unmutated H chain 
V region (unpublished data). These features closely mimic 
the Igs of B cells that undergo selection in the BM and possi-
bly escape tolerance induction to join the peripheral B cell 
pool (14). To generate the tg construct, the rearranged geno-
mic VDJ fragment of the 147 hybridoma was amplifi  ed 
by PCR and cloned into an IgM H chain expression vector 
(1). Using fl  ow cytometry and allotype-specifi  c antibodies, 
the tg Ig protein was expressed and allelically excluded rear-
rangement of endogenous Ig (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20060701/DC1).
The majority of anti-GPI B cells display an activated 
MZ phenotype in the spleen
VH147 tg mice were examined for the presence of anti-GPI 
B cells and were found to contain a readily detectable popu-
lation of GPI binders (Fig. 1 A). As one control, hen egg 
  lysozyme Ig tg mice on an IgM-defi  cient  background 
(HELμMT) were used as a population of non–GPI-binding 
B cells to defi  ne the GPI+ gate. VH147 tg mice contained 
populations of both anti-GPI and non-GPI B cells in the BM, 
spleen, LN, and peritoneal cavity with anti-GPI frequencies 
ranging from 6–13% of the total B cell population (Fig. 1 A 
and not depicted). This demonstrated that the VH147 trans-
gene signifi  cantly increased the frequency of GPI-binding B 
cells compared with transgene negative (tg neg) mice (0.6–
0.8% GPI+), allowing their fate to be followed in nonarthritic 
C57BL/6 mice. Analysis of total B cell numbers in VH147 tg 
mice revealed a decrease in the absolute number of B cells 
compared with tg neg littermates (6.8 ± 2.4 × 106 vs. 18.4 ± 
6.2 × 106; n = 12). This reduction in B cell numbers was not 
caused by a transgene integration artifact because a second in-
dependently derived founder line showed a similar decrease in 
B cell numbers (7.2 ± 4.7 × 106; n = 5). Decreased B cell 
numbers have also been noted in other H chain Ig tg mice 
and could be caused by deletion of some GPI-binding B cells 
in the BM and/or ineffi   cient pairing of the 147 H chain with 
many endogenous L chains (9, 10).
To characterize the anti-GPI B cell population in VH147 
tg mice, spleen and LN cells were stained with anti-B220, 
GPI-his protein, and a panel of cell surface markers used to 
defi  ne B cell subsets. Anti-GPI B cells in both the spleen and 
LN were found in the mature follicular compartment, 
B220highCD22highCD1dlowCD21/35intCD23int (Fig. 1 B). JEM VOL. 203, August 7, 2006  1987
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Intriguingly, the majority (59.5 ± 8.3%) of GPI-binding 
B cells in the VH147 tg spleen were not mature follicular 
B cells, but instead had the phenotype of MZ B cells, 
CD1dhighCD21/35highCD23low (Fig. 1 B). Consistent with an 
increase in MZ B cells, immunofl  uorescent staining of spleen 
sections revealed an expanded MZ in VH147 tg mice; how-
ever, we were unable to specifi  cally identify the GPI-binding 
B cells in the tissue sections because of their low affi   nity for 
GPI (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20060701/DC1; and not depicted). Preferential MZ 
B cell development has been reported previously in mice 
with reduced B cell numbers (20, 26, 27). Because VH147 tg 
mice had a 3–4-fold reduction in B cell numbers, it was 
  important to distinguish whether the enrichment of GPI-
binding B cells in the MZ was simply caused by lymphopenia. 
To address this, mixed BM chimeras (VH147 tg + tg neg) 
with a more complete B cell compartment (13.9 ± 4.8 × 
106 B cells; n = 4) were generated. The GPI-binding B cells 
Figure 1.  Anti-GPI B cells in the spleen exhibit an activated MZ 
phenotype, whereas those in the LN are naive mature follicular cells. 
Spleen or LN cells from VH147 tg or tg neg B6.K mice were stained with 
anti-B220, GPI-his, and antibodies against phenotypic markers or activation 
markers and analyzed by fl  ow cytometry. (A) The percentages of GPI-binding 
B cells out of total B220+ cells in the spleen are given for the boxed regions. 
The GPI+ gate was drawn based on the HELμMT, which contains a mono-
clonal population of non-GPI-binding B cells. (B) Histograms show surface 
marker expression for splenic or LN B220+GPI+ cells from VH147 tg mice 
(open histograms) overlaid tg neg B cells (shaded histograms). (C) Histo-
grams show activation marker expression for B220+GPI+ MZ (CD21/35high), 
FO (CD21/35int), or LN VH147 tg (open histograms) overlaid unfractionated 
tg neg B cells (shaded histograms). (D) Histograms are gated on 
B220+CD21/35high MZ B cells from the VH147 tg GPI+ (open histograms) 
overlaid GPI− (shaded histograms) populations. n = 5 mice of 
each genotype.1988  SITE-SPECIFIC ACTIVATION OF AUTOREACTIVE B CELLS | Mandik-Nayak et al.
were still enriched in the MZ compartment of the mixed 
BM chimeric mice (29.4 ± 2.3%) compared with tg neg 
  chimeric mice (4.1 ± 0.9%), but not to the same extent 
as in nonchimeric VH147 tg mice. FACS analysis of non-
GPI binders in both the VH147 spleen and LN, with the ex-
ception of an elevated level of CD23, closely matched tg neg 
B cells, demonstrating that the skewed MZ phenotype was 
specifi  c to the GPI-binding B cells (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20060701/DC1). 
This indicated that reduced B cell numbers may explain part 
of the MZ enrichment, but as suggested by others, self-
  reactivity is likely to have also played a role in their pheno-
typic skewing (21, 22, 24, 25).
To determine if the GPI-binding B cells in VH147 tg 
mice showed evidence of having encountered GPI Ag, the 
VH147 CD21/35high MZ and CD21/35int follicular splenic 
subsets, as well as LN cells, were stained for activation mark-
ers and compared with naive tg neg B cells (Fig. 1 C). Inter-
estingly, only the anti-GPI B cells in the MZ and not the 
follicle or LN of VH147 tg mice were activated, expressing 
elevated levels of CD44, CD69, CD80, and CD86 and an 
increase in cell size (Fig. 1 C). However, they had not formed 
germinal centers, as there was no evidence of an expanded 
germinal center B cell population in VH147 tg mice by im-
munofl  uorescence microscopy or fl  ow cytometry (not de-
picted). MZ B cells have been reported to be a partially 
activated population of B cells, possibly as a result of positive 
selection by autoantigen (22). In VH147 tg mice, the GPI-
binding MZ B cells expressed even higher levels of the acti-
vation markers CD44, CD69, CD80, and CD86 (1.5–3-fold 
elevated) compared with non-GPI binding VH147 or tg neg 
MZ B cells (Fig. 1 D and not depicted), indicating that their 
activation status was not simply a result of their MZ pheno-
type. Control non-GPI binders in both the spleen and LN 
did not express elevated levels of any of the activation mark-
ers tested (Fig. S3). Together, these data demonstrate that the 
majority of anti-GPI B cells in the spleen were activated MZ 
B cells, whereas a minority in the spleen and those in the LN 
remained naive mature follicular B cells.
MZ B cells exhibit the highest GPI autoantigen 
exposure in vivo
The diff  erences in activation phenotype suggested that the 
GPI-reactive B cells in the splenic MZ, follicle, and LN have 
Figure 2.  MZ B cells exhibit the highest exposure to GPI autoanti-
gen in vivo. (A) Cells from VH147 tg mice or HELμMT were stained with 
a pool of anti-GPI antibodies to determine the percentage of cells bound 
to endogenous GPI (top) or exogenous GPI followed by the pool of anti-
GPI mAbs to determine the total percentage of possible GPI-binders 
(bottom). The plots are gated on CD21/35+ cells for the HELμMT spleen, 
the VH147 blood and LN, IgM+ cells for the BM, CD21/35int cells for the 
follicle, and CD21/35high cells for the MZ. The percentages are given for 
the boxed regions. The positive gate is drawn based on the control 
HELμMT spleen sample. (B) The percentage of anti-GPI B cells bound to 
endogenous GPI was determined by dividing the percentage of cells 
  staining with anti-GPI antibodies alone by the total percentage of pos-
sible GPI binders. Each symbol represents an individual mouse for a total 
of n = 5 mice for each organ. The mean percentage of GPI-binding 
B cells is represented as a histogram. There is a signifi  cantly higher per-
centage of B cells bound to GPI in the MZ compared with the other organs 
(P < 0.0004) and a lower percentage bound in the BM (P < 0.025). The 
difference between the BM and peripheral blood is not statistically sig-
nifi  cant (P = 0.0687). BL, peripheral blood; FO, follicular. (C) The percent-
age of anti-GPI B cells bound to endogenous GPI in VH147 tg Cr2−/− 
mice. There is a signifi  cantly higher percentage of B cells bound to GPI in 
the MZ (P = 0.001; n = 3 mice).JEM VOL. 203, August 7, 2006  1989
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had diff  erent exposure to autoantigen. To address which popu-
lation exhibited the highest exposure to GPI and where 
GPI-reactive B cells fi  rst encountered their autoantigen, 
bound GPI was quantitated on anti-GPI B cells isolated from 
the BM, peripheral blood, LN, and spleen, separating MZ 
and follicular B cells, using fl  ow cytometry (Fig. 2, A and B). 
Not all B cells in VH147 tg mice are GPI-reactive; therefore, 
for this quantitation, we divided the percentage of cells bound 
to endogenous GPI by the percentage of total possible GPI 
binders. Endogenous GPI was bound to a percentage of anti-
GPI B cells in all organs tested. This indicated that anti-GPI 
B cells were fi  rst exposed to their autoantigen in the BM and 
continued to encounter it in the peripheral blood, spleen, 
and LN. Consistent with their activated phenotype, the high-
est percentage of GPI-bound B cells was found in the MZ, 
where 43.4 ± 4.8% of the total possible GPI-binding B cells 
were bound to GPI (Fig. 2 B). Because MZ B cells have high 
levels of the complement receptors (Crs) CD21/35 on their 
surface, the GPI could be bound directly to the Ig receptor as 
well as indirectly in the form of immune complexes (20). To 
test whether the increased endogenous GPI detected on the 
MZ B cells was caused by their elevated level of CD21/35, 
we bred the VH147 transgene onto a Cr-defi  cient (Cr2−/−) 
background (28). In the absence of Crs, the MZ pool still 
contained the highest percentage of B cells bound to endog-
enous GPI (Fig. 2 C). The percentage of GPI-bound B cells 
was actually higher in the MZ of Cr2−/− mice (70.1 ± 6.1%), 
perhaps because of the lack of other Cr-expressing cells in the 
MZ binding to GPI/anti-GPI immune complexes, leaving 
them free to bind the anti-GPI B cells via their Ig receptors.
The VH147 transgene is a H chain alone transgene. 
Therefore, it was possible that the activation diff  erences we 
observed were the result of diff  erential endogenous L chain 
usage by the anti-GPI B cells rather than increased Ag avail-
ability. To determine the L chains that generate GPI-binding 
Igs when paired with the VH147 H chain, L chains were 
cloned from anti-GPI B cells sorted from the spleen or LN. 
The majority of GPI binders in both the spleen (52%) and 
LN (84%) used the Vκ14-111 L chain (Fig. 3 A), the L chain 
used by the original KRN5-147 hybridoma. Sequences using 
other Vκ genes were also isolated, indicating that the VH147 
H chain could pair with several diff  erent L chains to generate 
an anti-GPI specifi  city (Fig. 3 A). Overall, the spleen and LN 
GPI-binding populations used a similar set of endogenous 
L chains; however, two Vκ sequences (Vκ9-124 and Vκ4-
52) were isolated only from the spleen and one Vκ sequence 
(Vκ17-121) only from the LN GPI-binders. To determine if 
there was any diff   erence in the relative affi   nity  of  these 
VH147/Vκ pairs compared with those found in both the 
spleen and LN populations, we isolated hybridomas using 
these L chains from unmanipulated VH147 tg mice. There 
was no clear distinction in the relative GPI affi   nity between 
the L chains found exclusively in the spleen and those found 
in both the spleen and LN (Fig. 3 B). Therefore, the spleen 
and LN GPI-binding B cells used similar endogenous L chain 
repertoires with the same relative affi   nity for GPI.
To show defi  nitively that MZ anti-GPI B cells were ex-
posed to more autoantigen in vivo and exclude minor recep-
tor affi   nity diff  erences not measurable in an ELISA assay, we 
used a H+L chain transgene (VH147+Vκ14-111) on a Rag−/− 
background (mk147 Rag−/−). This L chain was derived from 
the original KRN5-147 hybridoma. As expected, the B cells 
in mk147 Rag−/− mice strongly bound GPI (Fig. 4 A). 
  Importantly, both CD21/35highCD23low MZ and CD21/
35intCD23int follicular B cell subsets were present in mk147 
tg mice (Fig. 4 A). CD21/35highCD23low MZ B cells were 
increased in frequency in mk147 Rag−/− mice compared 
with tg neg mice (24.4 ± 1.9% vs. 5.7 ± 1.3%; P = 0.004; 
n  = 6); however, there was not the dramatic skewing 
Figure 3.  Spleen and LN B cells from VH147 tg mice use similar 
endogenous L chains. (A) L chain cDNA was amplifi  ed and cloned from 
sorted VH147 tg spleen or LN anti-GPI B cells as described in Materials 
and methods. L chain assignment was determined by using the Ig BLAST 
and IMGT/V programs. The percentage of sequences using the given 
L chains is depicted from a total of n = 25 sequences each from the 
spleen and LN. (B) Relative affi  nity ELISA of VH147 tg B cells paired with 
endogenous L chains. Purifi  ed Ig from VH147 tg hybridomas was plated 
on serially diluted GPI-his-biotin bound to neutravidin-coated wells. Igs 
with a higher relative affi  nity for GPI will bind to lower concentrations of 
GPI than Igs with lower relative affi  nities. The graph represents the mean 
OD ± SEM from triplicate wells, normalized as the fraction of maximal 
binding. This experiment was repeated twice using at least 2 hybridomas 
for each L chain, yielding similar results.1990  SITE-SPECIFIC ACTIVATION OF AUTOREACTIVE B CELLS | Mandik-Nayak et al.
  observed in VH147 tg mice (59.5 ± 8.3%). This indicated 
that, in addition to Vκ14-111, other L chains must have also 
contributed to the GPI-binding MZ repertoire in VH147 tg 
mice. The CD21/35highCD23low MZ B cells in mk147 
Rag−/− mice expressed a slightly higher level of CD23 and 
lower level of CD1d than MZ B cells in tg neg mice, the 
reason for which was not clear (Fig. 4 A).  However, when 
analyzed by histology, these CD21/35highCD23low B cells 
  localized to the MZ, confi  rming that they were MZ B cells 
and not a recently defi  ned CD21/35highCD23+ MZ precursor 
population that localized instead to the splenic follicle 
  (unpublished data) (27, 29).
The monoclonal B cell repertoire in mk147 Rag−/− mice 
allowed us to clearly test whether MZ and follicular anti-GPI 
B cells with identical B cell receptors still exhibited diff  er-
ences in autoantigen exposure (Fig. 4, B–D). Similar to the 
fi  ndings in VH147 tg mice, mk147 Rag−/− B cells from all 
organs tested had bound to GPI with the highest percentage 
of GPI-bound cells again found in the splenic MZ (40.9 ± 
6.2%; Fig. 4 C). Additionally, the MZ B cells demonstrated 
Figure 4.  Monoclonal anti-GPI tg mice have an expanded MZ 
population with increased in vivo autoantigen exposure. (A) Spleens 
from tg neg or mk147 Rag−/− mice were stained for GPI binders (left), MZ 
(CD21/35highCD23low) or follicular (CD21/35int/CD23low) populations gated 
on B220+ cells, or CD1d levels on CD21/35high (open histograms) overlaid 
CD21/35int (shaded histograms) B cells. The percentages of follicular and 
MZ cells are given for the indicated regions. (B) Cells from mk147 Rag−/− 
mice (open histograms) or HELμMT (shaded histograms) were stained for 
endogenously bound GPI as described in Fig. 2. The percentage and mean 
fl  uorescence intensity are given for the indicated regions. The mean 
percentage(C) and mean fl  uorescence intensity (D) of GPI-binding B cells 
± SEM are represented as histograms. There is a signifi  cantly higher per-
centage of B cells bound to GPI (P < 0.03) as well as intensity of GPI 
staining (P < 0.05) in the MZ compared with the other organs. BL, peri-
pheral blood; FO, follicular. n = 5 mice of each genotype. MFI, mean 
 fl uorescence intensity.JEM VOL. 203, August 7, 2006  1991
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the highest intensity of staining per cell (Fig. 4, B and D). 
Therefore, the B cells in the MZ, as a population, have 
  engaged more GPI than their counterparts in other compart-
ments. These data directly demonstrate that MZ B cells had 
greater access than follicular B cells to circulating autoanti-
gens, as had been suggested in previous studies (20, 21). Thus, 
the exclusive activation of MZ anti-GPI B cells was because 
a higher level of GPI autoantigen was available to them in 
the MZ.
Self-Ag encounter does not render anti-GPI B cells tolerant
Autoreactive B cells that have encountered their self-Ag are 
often rendered tolerant, such that they are refractory to sub-
sequent stimulation in vivo or in vitro (30). To determine 
whether the anti-GPI B cells were tolerant, spleen and LN 
cells were tested for their ability to proliferate and secrete Ig 
to in vitro stimuli. Anti-GPI B cells from both the VH147 tg 
spleen and LN proliferated robustly to LPS, anti-CD40 + 
IL-4, and cognate T cell help (KRN T cells) (Fig. 5 A). On 
day 3, anti-GPI Ig was detectable in the supernatants from 
VH147 tg spleen, but not LN, cells cultured with LPS, anti-
CD40 + IL-4, or KRN T cells (Fig. 5 B). By day 7, both 
VH147 tg spleen and LN cells had secreted anti-GPI Ig in 
response to LPS and KRN T cells (Fig. 5 C). The early anti-
body response by VH147 tg spleen cells together with their 
Ig secretion in response to anti-CD40 + IL-4 alone was con-
sistent with their MZ phenotype (22). None of the superna-
tants bound to plates coated with an irrelevant Ag, nor was 
anti-GPI Ig detected in the supernatants from tg neg B cells, 
confi  rming the specifi  city of the assay (Fig. 5, B and C; and 
not depicted). The tg neg spleen and LN B cells did exhibit a 
lower but detectable level of proliferation in response to 
KRN T cell help (Fig. 5 A). This low level of proliferation 
was most likely caused by a bystander response to factors such 
as CD40L and IL-4. In summary, despite their encounter 
with self-Ag, neither anti-GPI B cells in the spleen nor LN 
were rendered unresponsive to in vitro stimulation.
B cells that have not been tolerized should have a normal 
turnover rate in vivo (31). To estimate the turnover rate of 
anti-GPI B cells, VH147 tg or tg neg mice were continu-
ously labeled with BrdU for 15 d and analyzed by fl  ow cy-
tometry for the amount of incorporated BrdU in their spleens 
and LNs (Fig. 5 D). No diff  erence in the percentage of 
BrdU+ cells was detected between the VH147 tg anti-GPI 
B cells and tg neg B cells in either the spleen or the LN, nor 
was there a diff   erence when the cells were divided into 
CD21/35high MZ versus CD21/35low follicular populations 
(Fig. 5 D and not depicted). Previous experiments have dem-
onstrated that some autoreactive B cells have an accelerated 
turnover rate only when in the presence of nonautoreactive 
B cells (32). Although VH147 tg mice contained populations 
of GPI-binding and non–GPI-binding B cells, to ensure that 
their normal turnover rate was not caused by the lack of 
competition from non-tg B cells we measured the turnover 
Figure 5.  Anti-GPI B cells are not tolerant but proliferate and 
secrete Ig to in vitro stimuli and have a slow turnover rate in vivo. 
(A–C) Purifi  ed B cells from tg neg spleen, tg neg LN, VH147 spleen, or 
VH147 LN were cultured in vitro in media alone, 25 μg/ml LPS, 10 μg/ml 
anti-CD40 + 100 U/ml IL-4, or with purifi  ed KRN T cells. (A) Proliferation 
was measured on day 3 as a dilution of CFSE intensity, gating on 
B220+GPI+ VH147 tg or B220+ tg neg cells by fl  ow cytometry. Data is 
represented as the percentage of cells that divided ± SD (n = 3). 
A greater percentage of anti-GPI B cells proliferated to KRN T cells in the 
spleen (P = 0.0001) and LN (P = 0.0121) compared with tg neg B cells. 
Anti-GPI Ig secretion in the culture supernatants was measured on days 3 
(B) and 7 (C) by ELISA. Data is presented from a representative experiment 
of triplicate wells ± SD from a minimum of 3 experiments per culture 
condition. VH147 tg spleen cells produce a greater amount of anti-GPI Ig 
than tg neg spleen cells to LPS, anti–CD40+IL-4, and KRN T cells on days 
3 and 7 (P = 0.0001). VH147 tg LN cells produce more anti-GPI Ig than 
tg neg LN cells to LPS and KRN T cells on day 7 (P = 0.0001). (D) In vivo 
turnover rate. Mice were continuously labeled with BrdU for 15 d and 
followed for BrdU incorporation on days 6, 10, and 15 by fl  ow cytometry. 
Histograms represent the mean percentage of incorporated BrdU ± SD 
for VH147 GPI+ B cells or tg neg B cells. Four VH147 tg and three tg 
neg mice were analyzed at each time point. BM chimeras are shown 
for day 10 of BrdU labeling. n = 4 mixed chimeric, and n = 3 100% 
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rate of anti-GPI B cells in mixed BM chimeras (Fig. 5 D). 
The percentage of BrdU-labeled anti-GPI B cells was the 
same whether they were in the presence of tg neg B cells 
(mixed) or only VH147 B cells (100% VH147). Therefore, 
the anti-GPI B cells in VH147 tg mice had a normal in vivo 
turnover rate. This indicates that, although only the MZ 
B cells in the spleen had up-regulated activation markers in 
vivo, none of the anti-GPI B cell populations had been ren-
dered tolerant and all remained long-lived functionally com-
petent populations of autoreactive B cells.
Anti-GPI B cells in the MZ spontaneously secrete Ig
VH147 tg mice contain populations of anti-GPI B cells that 
are fully capable of producing Ig upon in vitro stimulation. 
To determine if these B cells were actively secreting antibody 
in vivo, we measured anti-GPI Ig in the serum by ELISA and 
anti-GPI antibody-secreting cells (ASCs) directly ex vivo by 
ELISPOT (Fig. 6). All VH147 tg mice expressed low but de-
tectable titers of anti-GPI Ig in the serum, whereas serum 
anti-GPI Ig was undetectable in tg neg littermate control 
mice (Fig. 6 A). This is consistent with GPI engagement on 
anti-GPI B cells not only up-regulating activation markers, 
but also resulting in the production of autoantibody. To 
quantitate which cells were secreting the autoantibody, ASCs 
were measured directly ex vivo in an ELISPOT assay. Anti-
GPI ASCs were detected from the spleen, but not the LN 
of VH147 mice (Fig. 6 B). The fact that only the MZ GPI 
binders up-regulated activation markers in response to their 
exposure to GPI in vivo suggested that they might be the 
population responsible for this autoantibody production. To 
directly test this, the ELISPOT assay was repeated using 
VH147 tg spleen samples that contained either purifi  ed fol-
licular B cells or an enriched population of MZ B cells (Fig. 
6 C). ASCs were present within the enriched MZ samples. 
However, ASCs were not found in the purifi  ed follicle sam-
ples that had been depleted of MZ B cells. Therefore, only 
the MZ anti-GPI B cells had diff  erentiated into ASCs in 
vivo. Collectively with Fig. 2, these data show that anti-GPI 
B cells in the MZ had encountered more GPI than their 
counterparts in the follicle or LN and in response became 
  activated to secrete autoantibody.
Anti-GPI B cells in the LN require T cell help to be recruited 
into the autoimmune response
In addition to the GPI-specifi  c B cells in the MZ, the recir-
culating follicular anti-GPI B cells are also a potentially dan-
gerous population of nontolerized autoreactive B cells with 
full functional capacity. However, unlike the anti-GPI B cells 
in the MZ, follicular and LN anti-GPI B cells were not acti-
vated nor did they secrete autoantibody in nonautoimmune 
mice. This leaves open the question of whether these igno-
rant anti-GPI B cells can play a role in the autoimmune re-
sponse in arthritic mice. To address whether recirculating 
follicular anti-GPI B cells could be recruited into the autoim-
mune response by autoreactive T cells in vivo, VH147 tg 
mice were given cognate T cell help by breeding them to 
KRN (anti-GPI TCR) tg mice on a (C57BL/6xNOD) 
F1 background. All of the VH147/KRN tg mice developed 
arthritis between 4–5 wk of age (Fig. 7 A). This was slightly 
delayed compared with their KRN littermates without the 
VH147 tg, most likely because of the IgM transgene skewing 
the B cells away from the pathogenic anti-GPI IgG1 Ig. Con-
sistent with this, VH147 tg mice also developed slightly lower 
Figure 6.  VH147 tg anti-GPI B cells in the splenic MZ but not 
follicle or LN spontaneously secrete Ig. (A) Serum anti-GPI Ig titers 
from VH147 tg or tg neg mice were measured by ELISA. Each symbol 
represents an individual mouse for a total of 19 VH147 and 16 tg neg 
mice. The mean serum titer is represented by a bar. VH147 tg serum has 
higher titers of anti-GPI Ig (P = 0.0001). (B) Spontaneous ASCs from the 
spleen or LN were measured by ELISPOT. Each symbol represents an indi-
vidual mouse for a total of n = 8 VH147 and n = 7 tg neg mice. The 
mean number of ASCs for each is represented by a histogram. More anti-
GPI ASCs are detected in the VH147 spleen compared with VH147 LN 
(P = 0.0002) or tg neg spleen or LN (P = 0.0003). (C) Spontaneous ASCs 
from purifi  ed follicular or MZ VH147 tg splenic B cells were measured by 
ELISPOT. Each symbol represents a pool of three mice with the mean 
number of ASCs represented by a histogram. Anti-GPI ASCs are found 
only in the MZ population (P = 0.0286). This experiment was repeated 
three times for a total of four pools of mice.JEM VOL. 203, August 7, 2006  1993
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serum titers of anti-GPI IgG1 (non-tg Ig) and total anti-GPI 
Ig titers (Fig. 7 B and not depicted). Importantly, however, 
VH147/KRN tg mice did develop arthritis with the same 
severity as their VH147 negative littermates (Fig. 7 A), and 
their serum anti-GPI Ig titers increased as disease progressed, 
unlike the constant low level of anti-GPI Ig detected in non-
autoimmune VH147 tg mice (Fig. 7 B). Therefore, these 
mice allowed us to determine whether the anti-GPI B cells in 
the recirculating follicular pool could be engaged in the au-
toimmune response.
To measure the anti-GPI B cell response in VH147/
KRN tg mice, the number of anti-GPI ASCs was assayed in 
the spleens and LNs of prearthritic and arthritic mice (Fig. 7, 
C and D). To distinguish between tg and non-tg Ig, both 
IgM (tg only; Fig. 7 C) and total Ig (tg + endogenous Ig; Fig. 
7 D) anti-GPI ASCs were counted. Pre-arthritic VH147/
KRN tg, like VH147 tg alone, mice contained IgM anti-GPI 
ASCs in the spleen (35.9 ± 9.6 ASCs/105 spleen cells), but 
not LN. Importantly, in arthritic VH147/KRN tg mice, IgM 
anti-GPI ASCs were now present in large numbers in the 
Figure 7.  Anti-GPI LN cells are recruited into the autoimmune 
response by in vivo T cell help. VH147 tg mice were bred to KRN tg 
mice on a (C57BL/6.K x NOD)F1 background and followed from 3–10 wk 
for the development of arthritis (A) and serum anti-GPI autoantibodies 
(B). VH147/KRN, KRN, and control mice (VH147 and tg neg) are shown. 
Symbols represent the mean ± SEM. n = a minimum of 8 mice per 
  genotype. (C) Spontaneous anti-GPI IgM (top) or total Ig (bottom) ASCs 
from the spleen or LN were measured by ELISPOT. Prearthritic mice were 
3 wk old, arthritic mice were 5–8 wk old, and control nonarthritic mice 
were 6–8 wk old. Each symbol represents an individual mouse for a mini-
mum of 5 prearthritic, 10 arthritic, and 5 nonarthritic control mice of 
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LNs (242.1 ± 64 ASCs/105 LN cells). In contrast, IgM anti-
GPI ASCs were low to undetectable in prearthritic or ar-
thritic KRN mice without the VH147 transgene, confi  rming 
that the ASCs were VH147 tg in origin. When total anti-GPI 
ASCs were compared between VH147/KRN and KRN tg 
alone arthritic mice, a similar large number of ASCs was 
found in the LN (VH147/KRN, 465.5 ± 116.2 ASCs/105 
LN cells; KRN, 512.3 ± 106 ASCs/105 LN cells). This indi-
cated that the VH147 tg anti-GPI ASCs were representative 
of the anti-GPI ASCs found in non-Ig tg arthritic mice with 
respect to both timing and location (Fig. 7 D) (33). Collec-
tively, these data demonstrate that although anti-GPI B cells 
in the recirculating B cell pool of VH147 tg mice were igno-
rant in nonautoimmune mice, they could be recruited into 
an autoimmune response by T cell help in vivo.
DISCUSSION
In this study we described a new Ig tg model, VH147, and 
used it to follow the fate of an oligoclonal population of low 
affi   nity GPI-reactive B cells. These mice revealed two func-
tionally distinct populations of anti-GPI B cells, one enriched 
in the splenic MZ and the other in the recirculating follicular 
pool. We demonstrated that, despite evidence of Ag encoun-
ter beginning in the BM and continued Ag binding in the 
periphery, none of the GPI-reactive B cells were rendered 
tolerant in nonautoimmune mice. However, only the anti-
GPI B cells in the MZ were activated and spontaneously se-
creted autoantibody in vivo. We also showed, using a H+L 
tg mouse, that the selective activation of these MZ GPI-
binders was caused by increased exposure to GPI autoantigen 
in the MZ and not to diff  erences in the relative affi   nity of 
these B cells compared with those in the follicular pool. Fi-
nally, we demonstrated that the recirculating follicular anti-
GPI B cells remained functionally competent and could be 
activated to secrete autoantibodies when given GPI-specifi  c 
T cell help in vitro and in vivo. This study shows that low af-
fi  nity anti-GPI B cells can contribute to autoantibody pro-
duction in both T cell–dependent and –independent ways 
and suggests that they have the potential to induce an arthri-
togenic autoimmune response.
Our low affi   nity VH147 tg model allowed us to make the 
important and surprising fi  nding that B cells were not toler-
ant to the ubiquitously expressed and circulating autoantigen 
GPI, despite evidence for binding to it in vivo. Stable and 
functional GPI exists as a homodimer (34) and therefore 
should be of suffi   cient valency to cross-link the BCR, as op-
posed to the monomeric Ags previously described to induce 
tolerance in B cells (35). However, the nontolerant B cells 
comprised two distinct populations. The GPI-specifi  c B cells 
in the MZ were activated because of their higher exposure to 
the circulating autoantigen. In contrast, those in the follicle/
LN were ignorant but could become activated when pro-
vided with T cell help. Ignorant self-reactive B cells with low 
affi   nity Ig receptor transgenes have been described previously 
(17, 19). In these models, it was proposed that the low affi   n-
ity interaction was not strong enough to either activate or 
  tolerize the B cells. This appears to be the case for the low 
level of Ag encountered by anti-GPI B cells in the recirculat-
ing follicular B cell pool. Strikingly, however, low affi   nity 
VH147 tg anti-GPI B cells in the MZ did show evidence of 
a productive Ag encounter. They had GPI bound to their Ig 
receptor and, in response, had both up-regulated activation 
markers and diff  erentiated into ASCs. The concept of diff  er-
ential ignorance/tolerance to autoantigens has also been de-
scribed before in the case of peritoneal B-1 B cells compared 
with their splenic B-2 counterparts and has been attributed to 
either increased susceptibility of B-2 B cells to tolerance 
  induction (36) or lack of Ag exposure in the peritoneum 
(37, 38). What is unique about our system is that we demon-
strated both ignorant and activated anti-GPI B cell popula-
tions, with compartmentalization into the MZ allowing these 
particular GPI-reactive B cells more access to their autoanti-
gen.  Because MZ B cells can be activated by lower levels of 
stimulation (22), the anti-GPI B cells in the MZ had a dual 
advantage over their counterparts in the follicle. They re-
quired less stimulation to become activated and, because of 
their anatomical location, encountered enough Ag to exceed 
that threshold.
Our fi  ndings diff  er considerably from a recently published 
high affi   nity anti-GPI Ig knock-in model in which the anti-
GPI B cells were tolerized, either by developmental arrest or 
through receptor editing (39). These features of tolerance 
have been described previously and are well-characterized 
fates for high affi   nity autoreactive B cells (1–5, 9–13). A strik-
ing diff  erence between the two models was that we found 
low affi   nity VH147 tg anti-GPI B cells were enriched in the 
splenic MZ, whereas they found no MZ enrichment of their 
anti-GPI B cells. This is consistent with the concept that 
there is an affi   nity threshold required for MZ B cell develop-
ment (21, 22, 24, 25). Finally, we demonstrated that our low 
affi   nity GPI-reactive B cells remained functionally compe-
tent to proliferate and secrete autoantibody in response to in 
vitro and in vivo stimuli, whereas their high affi   nity anti-GPI 
B cells were poorly responsive in vitro (39). Together, this 
reinforces the importance of studying B cells with low affi   n-
ity for self Ags.
The precise role of either the activated MZ or ignorant 
follicular/LN anti-GPI B cells in the pathogenic autoanti-
body response has not been established. Arthritis in K/BxN 
mice is dependent on high affi   nity IgG1 anti-GPI Igs (7). Not 
surprisingly then, the low affi   nity IgM autoantibodies secreted 
by the MZ B cells described here did not by themselves in-
duce disease. In VH147 tg mice, the activated MZ and igno-
rant follicular/LN autoreactive B cells exist concurrently, 
raising the possibility that they could act coordinately to initi-
ate the autoimmune response. Interestingly, MZ B cells have 
been shown to initiate immune responses by transporting 
IgM Ag-immune complexes into the follicle where they de-
posit them on follicular dendritic cells via receptors such 
as Cr1 and Cr2 (40). These experiments suggest that MZ B 
cells are in position to be the fi  rst responders to foreign Ags 
circulating in the blood and may be the catalyst for driving JEM VOL. 203, August 7, 2006  1995
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follicular B cell responses to these Ags. Likewise, MZ B cells 
would also be in close contact with autoantigens circulating 
in the blood and, if activated, could trigger autoimmune 
  responses. Indeed, we demonstrated that more anti-GPI 
B cells in the MZ than in the recirculating follicular compart-
ment have bound GPI. This raises the interesting possibility 
that these low affi   nity anti-GPI MZ B cells could augment 
the activation of pathogenic follicular B cells through the for-
mation and transport of IgM/GPI immune complexes. Alter-
natively, it is also possible that the low affi   nity anti-GPI IgM 
could play an inhibitory role, acting instead to clear GPI from 
the circulation via a complement-mediated process (41, 42). 
  Future experiments will be required to distinguish between 
these possibilities.
In K/BxN mice, the autoimmune response involves GPI-
reactive KRN T cells as well as anti-GPI B cells (7). We 
demonstrated that the LN/follicular anti-GPI B cells were 
able to be stimulated to produce anti-GPI autoantibodies by 
KRN T cells both in vitro and in vivo. The potential for 
T cell help to rescue/activate autoreactive B cells has been 
controversial. Activation of autoreactive B cells has been 
demonstrated in autoimmune mice; however, because of the 
lack of reagents to identify Ag-specifi  c T cells, the role of 
cognate T cell help could only be inferred (43–45). Other 
studies used surrogate forms of cognate T cell help and dem-
onstrated that anergy in autoreactive B cells was able to be 
prevented or even reversed in some systems, whereas in oth-
ers anergic B cells were not able to be rescued (46–49). These 
outcomes were attributed to diff  erences in the valency or 
avidity of the self-Ag studied and/or the timing and quality 
of T cell help. Our model is unique in that we are able to 
provide our self-reactive B cells with help from T cells rec-
ognizing the same well-defi  ned self-Ag, and all of this could 
be done during the development of autoimmunity. There-
fore, we were able to show directly that GPI-specifi  c B cells 
were stimulated to produce autoantibody by GPI-specifi  c 
T cell help during the development of arthritis in vivo. Al-
though the anti-GPI B cells in our study had a low affi   nity for 
self-Ag and therefore did not directly induce disease, we con-
tend that these nontolerant B cells are representative of auto-
reactive B cells that escape tolerance induction and, under 
the appropriate conditions, could initiate autoimmune re-
sponses. There is precedence in another autoantigen response 
suggesting that high affi   nity autoreactive B cells can be de-
rived from low affi   nity precursors (50). We propose then, 
that low affi   nity anti-GPI B cells can contribute to the auto-
antibody response by two distinct mechanisms depending on 
their compartmentalization. MZ anti-GPI B cells are sponta-
neously activated, whereas those in the follicle/LN require 
T cell help.
MATERIALS AND METHODS
Mice. KRN TCR tg C57BL/6 and K/BxN mice have been described pre-
viously (6). KRN and Rag-1−/− mice were crossed onto an H-2k back-
ground (B6.K; The Jackson Laboratory). HELμMT were obtained from 
Herbert W. Virgin (Washington University, St. Louis, MO) (51). Cr2-
  defi   cient mice, originally obtained from Hector Molina (Washington 
  University, St. Louis, MO) (28), were bred to VH147 tg mice and main-
tained in our colony. To obtain arthritic mice, VH147 tg B6.K mice were 
crossed to KRN B6.K mice and then subsequently crossed to NOD to gen-
erate VH147/KRN BxN mice. Tg mice were generated in the Washington 
University Department of Pathology transgenic core facility. Age-matched 
tg neg B6.K or tg neg (B6.K × NOD) F1 mice were used as controls in all 
experiments. All mice were bred and housed under specifi  c pathogen-free 
conditions in the animal facility at the Washington University Medical Cen-
ter. Experiments were performed in accordance with the National Institutes 
of Health and the Association for Assessment and Accreditation of Labora-
tory Animal Care guidelines.
Hybridoma generation. Unmanipulated spleen and LN cells from indi-
vidual arthritic K/BxN mice (6 wk old) or pooled VH147 B6.K mice 
(5 mice per fusion aged 6–8 wk each) were fused to the Ig− myeloma, SP2/0, 
as described previously (52). Cells were immediately plated at limiting dilu-
tion, and wells bearing single colonies were expanded for analysis. Hybrid-
omas were screened by ELISA for binding to GPI-his protein and for 
Ig isotype. The KRN5-147 hybridoma bound specifi  cally to GPI and not 
to the other cytoplasmic proteins, enolase, GAPDH, or hexokinase 
(unpublished data).
Flow cytometry. BM, spleen, peritoneal cavity, LN, and peripheral blood 
cells (106 each) were stained with commercially available antibodies (see 
Supplemental materials and methods, available at http://www.jem.org/cgi/
content/full/jem.20060701/DC1). mGPI-his protein was conjugated to bi-
otin using N-hydroxysuccinimidobiotin (Sigma-Aldrich) in our laboratory. 
For GPI receptor occupancy studies, cells were stained with anti-B220–APC, 
anti-CD21/35–PE (BD Biosciences), and an FITC-conjugated pool of anti-
GPI mAbs generated in our laboratory (KRN5-19, -28, -46, and -50.1) that 
bind to epitopes distinct from the KRN5-147 Ig, either with or without 
prior incubation with GPI-his.
All samples were analyzed on a fl  ow cytometer (FACSCalibur; BD Bio-
sciences) with CellQuest software (BD Biosciences). In some experiments 
the vital dye 7-amino-actinomysin D (Sigma-Aldrich) was added to exclude 
dead cells. Gating on live lymphocytes was based on forward and side scatter, 
and 50,000–100,000 events were collected for each sample.
BrdU labeling. Mice were labeled with 0.8 mg/ml BrdU (Sigma-Aldrich) 
in their drinking water for 15 d. The BrdU water was changed daily. Cells 
with an increased turnover rate as well as cells that were actively proliferating 
in the spleen and LN were labeled. To distinguish between proliferation and 
turnover, mice were pulsed with 1 mg/ml BrdU i.p. for 2 h to assess the in 
vivo proliferation status of the B cells. Only a small percentage of the GPI-
binding B cells in the spleen and LN incorporated BrdU during the 2-h 
pulse (0.8% VH147 vs. 1.2% tg neg; n = 3), indicating that they are not ac-
tively proliferating in vivo. Therefore, any BrdU+ cells detected during the 
15-d labeling were caused by replacement from labeled BM precursors.
BrdU staining was performed as previously described (12). In  brief, 
spleen and BM cells from mice were isolated and surface stained to identify 
GPI-binding MZ or follicular B cells as described in Flow cytometry. The 
cells were then fi  xed and permeabilized with 1% paraformaldehyde contain-
ing 0.1% Tween 20. The DNA was denatured using 10 μM HCl and 
100 U/ml DNaseI. The incorporated BrdU was then detected using an anti-
BrdU–FITC antibody (PRB-1) from eBioscience.
Anti-GPI ELISA. Serum samples, plated at an initial dilution of 1:50 and 
  diluted serially 1:2 (nonarthritic mice) or 1:10 (arthritic mice), or undiluted 
culture supernatants were plated in plates (Immulon II; Fisher Scientifi  c) coated 
with 5 μg/ml GPI-his. Donkey anti–mouse total Ig-horseradish   peroxidase 
(HRP; Jackson ImmunoResearch Laboratories) and goat anti–mouse IgM, 
IgG1, IgG2a, IgG2b, and IgG3-HRP (Southern Biotechnology Associates, Inc.) 
were used as secondary antibodies. Serum antibody was detected using a 
  substrate (ABTS; Roche Applied Science). The serum titer was defi  ned as the 
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Anti-GPI affi   nity ELISA. Igs were tested for their relative affi   nity for GPI 
by titration of binding in an ELISA assay as described previously (53). Hy-
bridoma IgM from tissue culture supernatant were purifi  ed using Immuno-
Pure immobilized mannan-binding protein according to manufacturer’s 
instructions, except that the supernatant was concentrated before dialysis into 
binding buff  er (Pierce Chemical Co.). 200 μg/ml purifi  ed hybridoma Igs 
were then tested in triplicate for binding to GPI-his, plated at an initial dilu-
tion of 10 μg/ml, and diluted serially 1:2 on Immulon II plates coated with 
10 μg/ml neutravidin. Goat anti–mouse IgM-HRP was used as a secondary 
antibody and detection was done as described for the anti-GPI ELISA.
Anti-GPI ELISPOT assay. Spleen or LN cells were plated at 4 × 105 
cells/well and diluted serially 1:4 in mixed cellulose ester membrane plates 
(Multiscreen HA; Millipore) coated with 5 μg/ml GPI-his. The cells were 
incubated on the Ag-coated plates at 37°C for 4 h. The Ig secreted by the 
plated cells was detected by alkaline phosphatase–conjugated goat anti–mouse 
total Ig or IgM secondary antibodies (Southern Biotechnology Associates) 
and visualized using NBT/BCIP substrate (Sigma-Aldrich).
Purifi   cation of MZ versus follicular B cells. Pooled spleens from 
VH147 tg mice (n = 3 per sample) were enriched for follicular or MZ B cells 
using a separation system (MACS; Miltenyi Biotech) in a two-step process. 
First, the cells were stained with anti-CD21–FITC and anti-CD23–PE, fol-
lowed by anti-PE paramagnetic beads (Miltenyi Biotech). The CD23+ 
(PE+) follicular B cells were collected as the positive fraction. The CD23− 
fraction was then bound to anti-FITC paramagnetic beads (Miltenyi Bio-
tech). The CD23−CD21+ MZ B cells were then collected as the positive 
fraction. Cell purity for follicular B cells was >90% with less than 1% con-
taminating MZ B cells. MZ B cells were enriched to 65% with 1–2% con-
taminating follicular B cells.
In vitro stimulation. B cells from tg neg or VH147 tg B6.K or (B6.K × 
NOD)F1 spleen and LN and KRN T cells were purifi  ed using the MACS 
separation system with paramagnetic anti-CD43 or anti-CD4 beads, respec-
tively. Cell purity was >95%. Cells were labeled with 5 μM CFSE (Invitro-
gen). 106 B cells were cultured in a 1-ml total volume in either media alone 
(Iscoves-DME, 10% FCS, 5 × 10−5 M 2-mercaptoethanol), 50 μg/ml LPS 
(Escherichia coli strain 0111:B4; Sigma-Aldrich), 10 μg/ml anti-CD40 
(clone 1C10; R&D Systems) + 100 U/ml IL-4 (grown as supernatant from 
IL-4–transfected P815 cells), or 0.5 × 106 KRN T cells. To determine if the 
VH147 tg anti-GPI B cells could respond to cognate T cell help, VH147 tg 
(B6.K × NOD) F1 mice were generated to obtain B cells that express the 
I-Ag7 MHC class II molecule for presentation of GPI peptide to KRN tg 
T cells (6). VH147 tg anti-GPI B cells have an identical surface phenotype in 
B6.K and (B6.K × NOD) F1 mice and therefore were used interchangeably 
(unpublished data). Proliferation was measured on day 3 by fl  ow cytometry 
as a decrease in CFSE intensity relative to unstimulated cells. Anti-GPI Ig 
secretion in tissue culture supernatants was determined on days 3 and 7 by 
anti-GPI ELISA.
Mixed BM chimeras. Lethally irradiated (1,000 Rad) B6.K mice were re-
constituted with 20 × 106 total BM cells containing either 95% VH147 + 
5% tg neg, 100% VH147 tg, or 100% tg neg cells. The resulting mixed chi-
meras contained  20% VH147 tg B cells. Chimeras were allowed to recon-
stitute for 6 wk and were then labeled with BrdU for 10 d before analysis.
Cloning and sequencing of VH147 L chains. GPI-binding B cells from 
VH147 tg spleen and LN, pooled from 15 mice each, were sorted using a 
high speed fl   ow cytometer (MoFlo; DakoCytomation). RNA from the 
sorted cell populations was isolated using the RNeasy kit (QIAGEN) and 
stored at −70°C before analysis. cDNAs were generated using a Cκ primer. 
L chain sequences were then amplifi  ed using the Cκ 3′ primer with the de-
generate 5′ primer, L3′ (52). The resulting PCR products were then cloned 
using a cloning kit for sequencing (TOPO TA; Invitrogen) and sequenced 
using a terminator mix (Big Dye; Applied Biosystems) and the M3 reverse 
primer from the vector sequence. L chain designation was determined by 
comparison to published sequences in the GenBank database using the Ig 
BLAST (available at http://www.ncbi.nlm.nih.gov/projects/igblast) and 
IMGT/V-Quest (http://imgt.cines.fr) programs. Alignment of L chain se-
quences using the same Vκ gene showed several nucleotide diff  erences 
within the V region (most yielding silent mutations) and usage of diff  erent 
Jκ genes, demonstrating that they were derived from independent clones 
(unpublished data).
Arthritis incidence. The two rear ankles were measured starting at the age 
of 3 wk. Measurement of ankle thickness was made above the footpad, 
axially across the ankle joint using a metric pocket thickness gauge (Fowler; 
Ralmikes Tool-A-Rama). Ankle thickness was rounded off   to the nearest 
0.05 mm.
Statistical analysis. Statistical signifi   cance was determined using an 
unpaired Student’s t test or the Mann-Whitney nonparametric test.
Online supplemental material. Fig. S1 shows the allelic exclusion of 
endogenous Ig by the VH147 transgene. Fig. S2 shows immunofl  uorescence 
staining demonstrating expanded MZs in VH147 tg mice. Fig. S3 shows 
phenotypic marker staining on control non-GPI binding B cells in VH147 
tg mice. Supplemental materials and methods include the cloning of the 
H and L chain genes for generating the tg Ig, generation of the recombinant 
GPI-his protein, antibodies used for fl  ow cytometry, and the immunofl  uo-
rescence staining protocol. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20060701/DC1.
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